GLP-1 Benefit Coverage
US$ 22.31
glp-1/fgf21 agonist boehringer Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research A novel GLP-1/FGF21 dual agonist
Description
Y., Gaspar, S., Deroisy, R., Zegels, B
References 1.Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al
Vildagliptin has been shown to lower the 24-hour glucagon profile when taken for four weeks at 100 mg once or twice daily (47, 54)
A medically supervised program ensures these treatments are tailored to your unique needs for safe and lasting results